DRG Epidemiology's coverage of colorectal cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of colorectal cancer for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the world.

DRG Epidemiology's colorectal cancer forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with colorectal cancer per year?
  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with colorectal cancer per year?
  • How will improvements in survival change the number of people living with a diagnosis of colorectal cancer?
  • How will decreasing recurrence risk change the number of first-line drug-treatment opportunities for colorectal cancer?
  • Of all people diagnosed with colorectal cancer, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of colorectal cancer over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.

In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following colorectal cancer subpopulations:

  • Stage II colon cancer.
  • Stage II rectal cancer.
  • Stage III colon cancer.
  • Stage III rectal cancer.
  • Stage IV colorectal cancer wild-type BRAF and RAS, first-line (left-sided).
  • Stage IV colorectal cancer wild-type BRAF and RAS, first-line (right-sided).
  • Stage IV colorectal cancer mutant RAS, first-line.
  • Stage IV colorectal cancer mutant BRAF, first-line.
  • Stage IV colorectal cancer wild-type BRAF and RAS,second-line (left-sided).
  • Stage IV colorectal cancer wild-type BRAF and RAS,second-line (right-sided).
  • Stage IV colorectal cancer mutant RAS, second-line.
  • Stage IV colorectal cancer mutant BRAF, second-line.
  • Stage IV colorectal cancer wild-type BRAF and RAS, third-line (left-sided).
  • Stage IV colorectal cancer wild-type BRAF and RAS, third-line (right-sided).
  • Stage IV colorectal cancer mutant RAS, third-line.
  • Stage IV colorectal cancer mutant BRAF, third-line.
  • … and many more (details available on request).

Note: coverage may vary by country.

Table of contents

  • Colorectal Cancer - Epidemiology - Mature Markets
    • Introduction
      • Key Findings
      • Key Updates
      • Diagnosed Incidence of Colorectal Cancer per 100,000 Per Year Among People of All Ages in 2019 and 2029
      • Patient Flow Diagram for Colorectal Cancer Across All Countries Under Study in 2019
      • Relative Sizes of the Contributing Factors to the Trend in Diagnosed Incident Cases of Colorectal Cancer over the Next Ten Years
      • Analysis of the Diagnosed Incident Cases of Colorectal Cancer in 2019 by Stage Distribution
      • Number of Diagnosed Incident Cases of Colorectal Carcinoma Avoided over 2019-2029 in the Countries Under Study
    • Epidemiology Data
    • Methods
      • Diagnosed Incident Cases
      • Stage Distribution of Colorectal Cancer
      • Recurrent Incident Cases of Colorectal Cancer
      • Diagnosed Prevalent Cases
      • Drug-Treatable Populations
      • Drug-Treated Populations
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Colorectal Cancer
        • Studies Excluded from the Analysis of Colorectal Cancer
      • Risk/Protective Factors
        • Bibliography

    Author(s): Mudasir Khan, M.P.H.

    Mudasir works as an associate epidemiologist within the epidemiology team at Decision Resources Group. He specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio.

    Mudasir holds a masters in public health specializing in epidemiology from TISS, Mumbai.


    Related Reports

    Colorectal Cancer - Landscape & Forecast - Disease Landscape & Forecast

    Chemotherapy remains the dominant cornerstone of colorectal cancer treatment and is prescribed with angiogenesis or EGFR inhibitors in the meta...

    View Details

    Colorectal Cancer | Disease Landscape and Forecast | G7 | 2020

    Targeted therapies and various biomarkers (e.g., RAS, BRAF, MSI-H,dMMR) play an important role in the treatment of colorectal cancer. Treatment is becoming increasingly segmented...

    View Details

    Colorectal Cancer - Geographic Focus: China - Colorectal Cancer - China In-Depth (China)

    Colorectal cancer, a major public health concern in China, is expected to become the second-most-common form of cancer there by 2029, behind only lung cancer. The treatment of metastatic colorectal...

    View Details

    Colorectal Cancer - Unmet Need - Detailed, Expanded Analysis (US/EU) Previously Treated RAS And BRAF Mutation-Positive Metastatic Colorectal Cancer

    This Unmet Need report focuses on the treatment of previously treated RAS and BRAF  mutation-positive metastatic colorectal cancer. Currently, the NCCN guidelines and treatme...

    View Details